Sociedad de Beneficencia Hospital Italiano - Córdoba
Sociedad de Beneficencia Hospital Italiano - Córdoba
Roma 550, Bº General Paz, Córdoba
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Virginia García
Rufino Caminos
Romina Gallo
Verónica Gabriela Savio
Valentina Bacceaga
Carla Alonso
Open studies
Breast Cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) - MK 2870-010 - Merck Sharp & Dohme LLCSee more
Cardiac arrhythmia
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation - LIBREXIA-AF - Janssen Research & Development, LLCSee more
Cervical cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
Head and neck cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Lung cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Ovarian cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Pulmonary hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients - APD811-301 - United TherapeuticsSee more
Solid tumors
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
